Abstract
Multiple outputs or measurement types are commonly gathered in biological experiments. Often, these experiments are expensive (such as clinical drug trials) or require careful design to achieve the desired information content. Optimal experimental design protocols could help alleviate the cost and increase the accuracy of these experiments. In general, optimal design techniques ignore between-individual variability, but even work that incorporates it (population optimal design) has treated simultaneous multiple output experiments separately by computing the optimal design sequentially, first finding the optimal design for one output (eg, a pharmacokinetic [PK] measurement) and then determining the design for the second output (eg, a pharmacodynamic [PD] measurement). Theoretically, this procedure can lead to biased and imprecise results when the second model parameters are also included in the first model (as in PK-PD models). We present methods and tools for simultaneous population D-optimal experimental designs, which simultaneously compute the design of multiple output experiments, allowing for correlation between model parameters. We then apply these methods to simulated PK-PD experiments. We compare the new simultaneous designs to sequential designs that first compute the PK design, fix the PK parameters, and then compute the PD design in an experiment. We find that both population designs yield similar results in designs for low sample number experiments, with simultaneous designs being possibly superior in situations in which the number of samples is unevenly distributed between outputs. Simultaneous population D-optimality is a potentially useful tool in the emerging field of experimental design.
Similar content being viewed by others
References
Breimer DD, Danhof M. Relevance of the application of pharmacokinetic-pharmacodynamic modelling concepts in drug development. The “wooden shoe” paradigm.Clin Pharmacokinet. 1997;32:259–267.
Levy G. The case for preclinical pharmacodynamics. In: Yacobi A, Skelly JP, Shah VP, Benet LZ, eds.Integration of Pharmacokinetics. Pharmacodynamics and Toxicokinetics in Rational Drug Development. New York, NY: Plenum Press, 1993:7–13.
Gabrielsson JH, Luthman J, van der Graaf PH. Utility of kineticdynamic reasoning in decision making in drug candidate selection. In: Danhof M, Karlsson M, Powel RJ, eds.Measurement and Kinetics of In Vivo Drug Effects.Advances in Simultaneous Pharmacokinetic/ Pharmacodynamic Modelling.Vol 1. The Netherlands: Nordwijkerhout; 2002:161–165.
US Food and Drug Administration. FDA Modernization Act of 1997. Food and Drug Administration Web site. Available at: www.fda.gov. Accessed October 2003.
US Food and Drug Administration. Providing clinical evidence of effectiveness for human drugs and biological products. Food and Drug Administration Web site. Available at: www.fda.gov. Accessed October 2003.
D’Argenio DZ. Optimal sampling times for pharmacokinetic experiments.J Pharmacokinet Biopharm. 1981;9:739–756.
US Congress.Pharmaceutical R&D: Costs, Risks and Rewards. Washington, DC: US Government Printing Office, 1993:OTA-H-522.
Kaitin KI.Outlook 2002. Boston, MA: Tufts Center for the Study of Drug Development, Tufts University; 2002.
al-Banna MK, Kelman AW, Whiting B. Experimental design and efficient parameter estimation in population pharmacokinetics.J Pharmacokinet Biopharm. 1990;18:347–360.
Retout S, Mentre F, Bruno R. Fisher information matrix for nonlinear mixed-effects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics.Stat Med. 2002;21:2623–2639.
Atkinson AC, Donev AN.Optimum Experimental Designs. Oxford, UK: Clarendon Press, 1992.
Tod M, Padoin C, Louchahi K, Moreau-Tod B, Petitjean O, Perret G. Application of optimal sampling theory to the determination of metacycline pharmacokinetic parameters: effect of model misspecification.J Pharmacokinet Biopharm. 1994;22:129–146.
Landaw EM. Robust sampling designs for compartmental models under large prior Eigenvalue uncertainties. In: Eisenfeld J, DeLisi C, eds.Mathematics and Computers in Biomedical Applications, North-Holland, The Netherlands: Elsevier Science Publishers BV; 1985:181–187.
Duffull SB, Mentre F, Aarons L. Optimal design of a population pharmacodynamic experiment for ivabradine.Pharm Res. 2001;18:83–89.
Mentre F, Dubruc C, Thenot JP. Population pharmacokinetic analysis and optimization of the experimental design for mizolastine solution in children.J Pharmacokient Pharmacodyn. 2001;28:299–319.
Mentre F, Mallet A, Baccar D. Optimal design in random-effects regression models.Biometrika. 1997;84:429–442.
Retout S, Duffull S, Mentre F. Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs.Comput Methods Programs Biomed. 2001;65:141–151.
Merle Y, Tod M. Impact of pharmacokinetic-pharmacodynamic model linearization on the accuracy of population information matrix and optimal design.J Pharmacokinet Pharmacodyn. 2001;28:363–388.
Zhang L, Beal SL, Sheiner LB. Simultaneous vs sequential analysis for population PK/PD data I: best-case performance.J Pharmacokinet Pharmacodyn. 2003;30:387–404.
Danhof M, Karlsson M, Powell RJ, eds. Advances in Simultaneous Pharmacokinetic/Pharmacodynamic Modelling. Part 1 and 2 4th International Symposium on measurement and Kinetics of In Vivo Drug Effects; April 24–27; Nordwijkerhout, The Netherlands. Leiden, The Netherlands: Leiden University; 2002. 1–200.
Davidian M, Giltiman DM.Nonlinear Models for Repeated Measurement Data. New York, NY: Chapman & Hall/CRC; 1995:241.
Fedorov VV, Hackl P.Model Oriented Design of Experiments. New York, NY: Springer-Verlag, 1997.
Vonesh EF, Chinchilli VM.Linear and Nonlinear Models for the Analysis of Repeated Measurements. New York, NY: Marcel Dekker Inc; 1997.
Hooker AC, Foracchia M, Dodds MG, Vicini P. An evaluation of population D-optimal designs via pharmacokinetic simulations.Ann Biomed Eng. 2003;31:98–111.
Foracchia M, Hooker A, Vicini P, Ruggeri A. POPED, a software for optimal experiment design in population kinetics.Comput Methods Programs Biomed. 2004;74:29–46.
Larsen RJ, Marx ML.An Introduction to Mathematical Statistics and Its Applications. Upper Saddle River, NJ: Prentice-Hall; 1986:248.
Solkner J. Choice of optimality criteria for the design of crossbreeding experiments.J Anim Sci. 1993;71:2867–2873.
Retout S, Mentre F. Further developments of the Fisher information matrix in nonlinear mixed effects models with evaluation in population pharmacokinetics.J Biopharm Stat. 2003;13:209–227.
Sheiner L, Wakefield j. Population modelling in drug development.Stat Methods Med Res. 1999;8:183–193.
Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine.Clin Pharmacol Ther. 1979;25:358–371.
Draper NR, Hunter WG. Design of experiments for parameter estimation in multiresponse situations.Biometrika. 1966;53:525–533.
Bennett JE, Wakefield JC. A comparison of a Bayesian population method with two methods as implemented in commercially available software.J Pharmacokinet Biopharm. 1996;24:403–432.
Hashimoto Y, Sheiner LB. Designs for population pharmacodynamics: value of pharmacokinetic data and population analysis.J Pharmacokinet Biopharm. 1991;19:333–353.
Colburn WA. Simultaneous pharmacokinetic and pharmacodynamic modeling.J Pharmacokinet Biopharm. 1981;9:367–388.
Mandema JW, Stanski DR. Population pharmacodynamic model for ketorolac analgesia.Clin Pharmacol Ther. 1996;60:619–635.
Beal S, Sheiner L.NONMEM User’s Guide. San Francisco, CA: University of California; 1992.
Holford N, Hashimoto Y, Sheiner LB. Time and theophylline concentration help explain the recovery of peak flow following acute airways obstruction. Population analysis of a randomised concentration controlled trial.Clin Pharmacokinet. 1993;25:506–515.
Mager DE, Jusko WJ. Receptor-mediated pharmacokinetic/ pharmacodynamic model of interferon-beta la in humans.Pharm Res. 2002;19:1537–1543.
Author information
Authors and Affiliations
Corresponding author
Additional information
Published: November 1, 2005
Rights and permissions
About this article
Cite this article
Hooker, A., Vicini, P. Simultaneous population optimal design for pharmacokinetic-pharmacodynamic experiments. AAPS J 7, 76 (2005). https://doi.org/10.1208/aapsj070476
Received:
Accepted:
DOI: https://doi.org/10.1208/aapsj070476